Hospital medication markups are the difference between what hospitals pay for drugs and what they charge patients or insurance—and the gap is staggering. Research from the New England Journal of Medicine in 2024 found that hospitals eligible for federal 340B drug discounts charged patients 6.59 times the prices charged by independent physician practices for the same drugs, with median markups of 3.08 times the acquisition cost. The scale is hospital-wide.
An analysis of 3,792 hospitals using CMS data found average markups of approximately 500%, and one in five hospitals marked up some drugs by more than 1,000%. For patients with insurance, these inflated prices mean higher out-of-pocket costs. For uninsured patients, they can be the difference between receiving treatment and going into debt.
Table of Contents
- How Much More Do Patients Pay at Hospitals?
- The 340B Program and Why It Failed Patients
- Real-World Pricing Examples
- Transparency and What Patients Cannot See
- What Is Changing
- Frequently Asked Questions
How Much More Do Patients Pay at Hospitals?
The multiplier varies by drug and setting, but the pattern is consistent across payers. Patients pay three to seven times more for outpatient medications at hospitals than at other care settings like independent clinics or physician offices. The highest markups appear in specialty infusions and cancer treatment. Chemotherapy pricing shows the impact most clearly.
Chemotherapy treatment costs approximately 60% more at hospitals than at independent community oncology practices, directly affecting out-of-pocket costs for cancer patients. A single infusion can run thousands of dollars higher at a hospital than at a nearby cancer clinic—the same drug, the same patient, different venue.
The 340B Program and Why It Failed Patients
The 340B drug discount program was created to help nonprofits and safety-net hospitals reduce medication costs and reinvest savings into patient care. Instead, many hospitals have used it to widen the gap between acquisition cost and patient price. Under 340B, hospitals buy drugs at steep discounts from manufacturers. One large nonprofit hospital system, Cleveland Clinic, generated $933.7 million in revenue from the 340B drug discount program over three years by purchasing discounted drugs and charging patients inflated prices.
The discount was meant to be passed to patients or reinvested in care—not kept as markup revenue. A Third Way analysis found that nearly half of hospitals using 340B discounts are consolidating pricing power rather than reducing patient costs.
Real-World Pricing Examples
The gap between hospital and clinic pricing is not theoretical. In one documented case, an oxaliplatin infusion was priced at $13,560 at one hospital while a nearby clinic charged $134 for the same drug, illustrating how dramatically prices can vary within the same market. Patients facing chemotherapy often do not know these alternatives exist, or they believe their oncologist's hospital is their only option.
These disparities affect real out-of-pocket costs. If an insurer's coinsurance is 20%, a patient pays $2,712 at the hospital and $26.80 at the clinic for the same drug. Even with good insurance, the hospital markup flows directly to the patient's deductible and out-of-pocket maximum.
Transparency and What Patients Cannot See
Federal rules require hospitals to publish pricing for high-expenditure medications. In practice, this requirement has failed. Only 62% of hospitals currently provide usable pricing data for high-expenditure medications despite federal transparency requirements, preventing patients and employers from comparing prices before treatment. Even when prices are published, they are often incomprehensible—bundled with facility fees, listed without the patient's actual copay or coinsurance, or offered in formats that do not allow meaningful comparison. A patient cannot reliably know in advance what an infusion will cost at their hospital versus a clinic across town.
What Is Changing
Federal regulators are beginning to address the information gap that has allowed these markups to persist. CMS is now conducting the first federally mandated survey (ODACS) to directly measure hospital acquisition costs for 1,843 drugs, with results to inform Medicare payment policy changes in 2027—acknowledging that prior payment rates lacked actual cost data. This survey will establish for the first time what hospitals actually pay manufacturers, creating a factual baseline to evaluate markups.
This change is years away and applies to Medicare first. It does not address the broader problem of nonprofits using 340B discounts to inflate patient prices. But it marks the first moment when regulators will have concrete data about hospital acquisition costs rather than estimates—and the first opportunity to tie hospital reimbursement to reality instead of legacy rates designed in an era of transparency.
Frequently Asked Questions
Can I ask my hospital for a lower medication price?
You can ask, but hospitals are not required to discount for uninsured patients. If you are facing a high medication bill, ask for a financial assistance application or cash-pay discount. Some hospitals will negotiate; most do not. Getting a price estimate in writing before treatment is always worth attempting, and if a clinic alternative exists nearby, asking whether they charge differently.
Does my insurance cover the difference between hospital and clinic prices?
Your insurance pays the claim the same way regardless of setting (usually), but your coinsurance, copay, or deductible applies to the hospital's billed amount. If a hospital charges $13,560 and a clinic charges $134, and your coinsurance is 20%, you pay $2,712 at the hospital and $26.80 at the clinic. Ask your plan what your out-of-pocket cost will be before choosing a facility if you have that choice.
What does the 340B program do?
It lets nonprofit hospitals, safety-net hospitals, and certain clinics buy drugs at manufacturer discounts. The law says the savings should go to patients or reinvestment in care. Many hospitals have instead used the discount to buy cheap and sell expensive—generating revenue rather than patient benefit.